EISAI CO LTD

Discover how EISAI’s diversified EGFR‑targeted pipeline—spanning small molecules, bispecific antibodies, and ADCs—positions the company to lead the next wave of precision oncology therapies.

Explore Eisai’s FY 2029 outlook: Leqembi’s projected ¥300 bn revenue, robust AD data, and growth in Dayvigo and Lenvima – a balanced neuro‑oncology strategy.

Discover how Eisai’s lenvatinib strategy and upcoming ASCO data could reshape oncology pricing and market share, balancing cost‑efficiency with patient outcomes.

Discover how Eisai’s Q1 2026 results show a modest EPS decline yet strong revenue growth, driven by breakthrough trials in Alzheimer’s, obesity, and oncology.

Leqembi sales to hit ¥143.5 bn in FY 2026, driving a 35% rise in Eisai’s attributable profit and solidifying its role in global Alzheimer’s care.

Read how Eisai’s LITESPARK‑012 failure reshapes its RCC strategy and what Merck & Co. can learn for future oncology collaborations.

Neutral interim results from Eisai’s LITESPARK‑012 trial show adding a HIF‑2α inhibitor to anti‑PD‑1 plus kinase inhibitor doesn’t improve survival in advanced RCC.

How the Cochrane review debunks Alzheimer’s antibody therapies, exposes safety risks, and reshapes market & regulatory expectations for the future of neuro‑degenerative treatments.

Explore how Eisai’s strategic collaborations with Allarity Therapeutics and Newron Pharmaceuticals accelerate oncology drug development, boosting patient outcomes and market reach.

Explore Eisai’s 2025 results and 2026 outlook for lecanemab, highlighting long‑term patient retention, safety, and FDA/EMA regulatory prospects in Alzheimer’s therapy.